The study focused on the application of high-resolution mass spectrometry for the identification of impurities in pharmaceutical small molecules. A high-performance liquid chromatography (HPLC) coupled high resolution mass spectrometer (HRMS) was used for identification of oxidative degradation impurities (DIs) of lansoprazole. The utilization of HRMS facilitates to determine the accurate mass of impurities and their fragment/product ions. A fast mass spectrometer (MS) compatible reverse phase chromatography method was used to investigate the oxidative stressed impurities. HPLC column; C18 (50 × 4.6 mm, 3.5 µm) was used with gradient elution. Spectral data acquired using information dependent acquisition (IDA) with real time dynamic background subtraction algorithm (DBS). Three oxidative impurities: DI-I (m/z 386.0781), DI-II (m/z 402.0734) and DI-III (m/z 386.0785), was observed during this study; interpretation of high resolution spectral data of all three impurities was carried out; elemental composition and molecular structure was proposed for major fragments. In this study mass error was found ≤7.7 parts per million (ppm).
Introduction
Structural analysis of degradation impurities is one of the essential studies in pharmaceutical analysis, particularly during the product development process [1] . The safety of any drug product is not only depending on the toxicological Int. J. Analytical Mass Spectrometry and Chromatography properties of the active drug substance, but also on the impurities present in it; monitoring and the control of degradation impurities in pharmaceuticals is a key element of the guidelines issued by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) [2] [3] [4] .
There are many analytical techniques which are commonly being used for impurity profiling, high pressure liquid chromatography (HPLC) coupled with ultraviolet (UV) or photo diode array (PDA) detector is one of the most common analytical techniques to estimate the degradation impurities. But the identification and structural confirmation of the degradation products is done by using MS detectors i.e. Triple quadrupole, ion trap, and high resolution mass spectrometers (time of flight and orbitrap) [5] [6] [7] . For this study time of flight high-resolution mass analyzer selected; use of high resolution mass spectrometer facilitates accurate measurement of m/z values, which supports to propose the exact elemental compositions and to predict the structure of parent and product ions [8] [9] [10] [11] . Oxidation sensitive drug molecule lansoprazole was selected for this study. Lansoprazole [12] [13] [14] belongs to a group of drugs called proton pump inhibitors, which inhibits the stomach's production of gastric acids. Physically, it is a white to brownish-white odorless crystalline powder and chemically known as g/mol and its monoisotopic molecular weight is 369.0759. Molecular structure and exact mass of lansoprazole molecule is presented in Figure 1 .
The goal of present study was identification of the oxidative degradation impurities of lansoprazole using high-resolution MS and MS/MS analysis, two oxidation impurities (USP impurities-"N-Oxide" and "related compound A") of lansoprazole are specified impurity in US pharmacopeia [15] and other impurities discussed in several other research publications [16] [17] [18] ; during this study one unspecified oxidative impurity (di-oxidized) with m/z 402.0734 was observed; high-resolution mass spectral data of lansoprazole and its oxidative impurities generated using electrospray ionization and collision induced dissociation. Followed by interpretation of spectral data using basic interpretation rules and workflow [19] [20] ; elemental composition, molecular structures proposed and mass error calculated for major m/z values.
Experiment

Material
The ultrapure water (18.2 MΩ) was obtained using MilliQ apparatus; manufactured by Millipore, USA. Mass spectrometry grade solvents methanol and acetonitrile; manufactured by J.T. Baker, USA. meta-chloroperbenzoic acid (m-CPBA); manufactured by Sigma-Aldrich, USA. Ammonium acetate and sodium hydroxide; manufactured by Merck, India. The lansoprazole was extracted from commercially available generic dosage form; manufactured by Intas Pharmaceutical, India. Powdered and finally extracted in diluent acetonitrile, methanol and 0.1 N sodium hydroxide, (5:2:3). The solution was centrifuged and supernatant was subjected to degradation study.
Instruments and Conditions
Prominence 20AD HPLC (from Shimadzu corporation, Kyoto, Japan) with UV 
Result and Discussion
Three oxidative degradation products/impurities of lansoprazole (DS) was identified using HRMS. Simultaneous acquisition of MS and MS/MS data was developed using non-targeted generic (IDA) method with real time background subtraction. All three degradation impurities of oxidative stressed condition were identified using full scan mass spectra and their product ion data at chro- The proposed interpretation of fragments summarized in Table 3 and Figure 6 ; fragment ion 268.0256 (calculated formula C 9 H 9 F 3 NO 3 S + , exact mass Table 3 and Figure 6) further confirms DI-I as USP N-oxide impurity; refer Figure 9 .
In full scan spectrum of DI-II, molecular ion peak was found as 402.0734
[M+H] + (refer Figure 3) The interpretation of fragments summarized in Table 4 and Figure 7 ; frag- Table 4 and 
Conclusion
In this study, generic IDA method developed using high-resolution mass spectrometry system to identify and confirm the lansoprazole degradation impurities under oxidative stressed condition. Generic information dependent acquisition 
